ArticleCommunications medicine2026
Hormonal contraceptives and EEG biomarkers for antidepressant treatment response in women.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWomen are disproportionately affected by major depressive disorder (MDD). Widely used hormonal contraceptives are linked to depression and altered brain function, yet their unstudied impact on EEG-biomarkers of antidepressant response may confound efforts to develop biomarkers for women.
methodsIn 60 unmedicated premenopausal women with MDD: non-users (n = 25), combined oral contraceptive users (COC, n = 19), and progestin-only contraceptive users (POC, n = 16), we assess five EEG-biomarkers before eight weeks of 10-20 mg escitalopram: Alpha peak frequency (APF), Vigilance level, Loudness-Dependence of Auditory Evoked Potentials (LDAEP), frontal alpha asymmetry (FAA), and theta activity at the anterior cingulate cortex (tACC). Analyses include age-adjusted ANCOVAs, hierarchical logistic regression, and repeated LASSO-regressions to evaluate the effects of hormonal contraceptives on EEG-biomarkers and treatment response.
resultsNo differences between contraceptive groups are found in EEG-biomarkers (ω²<0.03, p > 0.15). Adding contraceptive groups improves EEG-based predictions for all biomarkers (p < 0.044). While hierarchical regressions show no significant EEG-biomarker contraceptive-group interactions, LASSO-regressions select contraceptive status in interaction with APF and tACC in models that best predict treatment outcome. Disregarding EEG, hormonal contraceptive use is associated with treatment response (p = 0.01). COC-users exhibit lower response rates than non-users (24% vs 71%, OR = 0.14 [0.03, 0.65], p = 0.012). POC-users have a 44% response rate (p = 0.140).
conclusionsAlthough hormonal contraceptive use is not associated with EEG-biomarkers in unmedicated depressed women, they may modulate links between specific EEG-biomarkers and antidepressant response. However, contraceptive use, specifically COC, is associated with worse treatment outcomes and may be critical to developing biomarkers, including EEG-based, to guide treatment in women with MDD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.